UNSPSC 51161705: Ipratropium bromide

This classification denotes a bronchodilator and antimuscarinic agent with the molecular formula C20H30NO3.Br.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J697UZ2A9J, chemically known as 3-alpha-hydroxy-8-isopropyl-1-alpha-h,5-alpha-h-tropanium bromide (+-)-tropate but generally known as ipratropium bromide, which bears US NIH Compound Identifier 31098. European Medicines Agency schedules Ipratropium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08276MIG.

UNSPSC 51161705 Ipratropium bromide is a Commodity code that nominally describes a specific pharmaceutical agent, but recent state and local procurement activity under this code shows a fundamental mismatch — the opportunities posted are for naloxone procurement, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply contracts, none of which involve ipratropium bromide as a primary deliverable. The code's tagging appears to be a classification error rather than a reflection of actual purchasing patterns. State and local issuing bodies soliciting pharmacy-related goods and services span county health departments (Seminole County, Florida), county government employee health clinics (Hall County, Georgia), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of work being solicited ranges from specific pharmaceutical products like naloxone and safe drug deactivation systems through comprehensive on-site pharmacy services for employee health plans to broad-based generic pharmaceutical supply agreements with authorized wholesalers and direct-to-manufacturer contracting models.

Geographic activity is concentrated in the Southeast and Southwest, with recent solicitations from Florida, Georgia, Texas, and Minnesota (serving multiple states including Oregon). Representative opportunities include Seminole County's IFB60459723LAS (IFB, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems delivered quarterly; Hall County's RFQ/P #47-010 (RFQ with cost proposal, due June 4, 2026) for on-site pharmacy services at the Family Health Center Clinic in Gainesville, Georgia, serving approximately 3,005 eligible individuals across multiple insurance plans with an 80/20 technical-to-cost scoring structure; Texas HHS Commission's RFI HHS0017013 (Request for Information, posted April 3, 2026) exploring direct-to-manufacturer prescription programs; and MMCAP's multi-state RFP S1070000015802 (RFP, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers. The code shows little relevant activity aligned with its nominal pharmaceutical agent focus.